ondansetron has been researched along with Heart Septal Defects, Ventricular in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Heart Septal Defects, Ventricular: Developmental abnormalities in any portion of the VENTRICULAR SEPTUM resulting in abnormal communications between the two lower chambers of the heart. Classification of ventricular septal defects is based on location of the communication, such as perimembranous, inlet, outlet (infundibular), central muscular, marginal muscular, or apical muscular defect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Literature is divided regarding the risk of neonatal ventricular septal defect (VSD) associated with first trimester ondansetron use in pregnancy." | 7.96 | Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. ( Bodnar, LM; Caritis, SN; Garrard, W; Lemon, LS; Marroquin, OC; Platt, RW; Venkataramanan, R, 2020) |
| "Literature is divided regarding the risk of neonatal ventricular septal defect (VSD) associated with first trimester ondansetron use in pregnancy." | 3.96 | Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. ( Bodnar, LM; Caritis, SN; Garrard, W; Lemon, LS; Marroquin, OC; Platt, RW; Venkataramanan, R, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lemon, LS | 1 |
| Bodnar, LM | 1 |
| Garrard, W | 1 |
| Venkataramanan, R | 1 |
| Platt, RW | 1 |
| Marroquin, OC | 1 |
| Caritis, SN | 1 |
1 other study available for ondansetron and Heart Septal Defects, Ventricular
| Article | Year |
|---|---|
Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect.
Topics: Female; Heart Septal Defects, Ventricular; Humans; Infant, Newborn; Ondansetron; Pregnancy; Pregnanc | 2020 |